Diabetic retinopathy in the Eastern Morocco: Different stage frequencies and associated risk factors

被引:8
作者
Hammoudi, Jamila [1 ]
Bouanani, Nour El Houda [1 ]
Chelqi, El Habri [2 ]
Bentata, Yassamine [3 ]
Nouayti, Hamid [1 ]
Legssyer, Abdelkhaleq [1 ]
Ziyyat, Abderrahim [1 ]
机构
[1] Univ Mohammed Premier, Dept Biol, Lab Bioressources Biotechnol Ethnopharmacol & San, Fac Sci, Oujda 60000, Morocco
[2] Clin Al Irfane Oujda, Serv Ophtalmol, Oujda, Morocco
[3] CHU Mohammed VI, Serv Nephrol, Oujda, Morocco
关键词
Diabetic retinopathy; Diabetic nephropathy; Eastern Morocco; Risk factors; RETINAL MICROVASCULAR ABNORMALITIES; GLOBAL PREVALENCE; ADULT-POPULATION; GLYCEMIC CONTROL; KIDNEY-DISEASE; NEPHROPATHY; TYPE-1; DIAGNOSIS; MELLITUS; HEALTH;
D O I
10.1016/j.sjbs.2020.11.010
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Diabetes is a major cause of morbidity and mortality worldwide. It can affect many organs and, over time, leads to serious complications. Diabetic retinopathy (DR), a specific ocular complication of diabetes, remains the leading cause of vision loss and vision impairment in adults. This work is the first in Eastern Morocco aimed at identifying the different stages of DR and to determine their frequencies and associated risk factors. It is a case-control study conducted from December 2018 to July 2019 at the ophthalmology department of Al-Irfane Clinic (Oujda). Data were obtained from a specific questionnaire involving 244 diabetic patients (122 cases with retinopathy vs 122 controls without retinopathy). All results were analyzed by the EPI-Info software. This study shows a predominance of proliferative diabetic retinopathy (PDR) with 57.4% of cases (uncomplicated proliferative diabetic retinopathy (UPDR): 23.8%; complicated proliferative diabetic retinopathy (CPDR): 33.6%). The non-proliferative diabetic retinopathy (NPDR) represents 42.6% (minimal NPDR: 8.2%; moderate NPDR: 26.2%; severe NPDR: 8.2%). The determinants of DR were insulin therapy, high blood pressure, poor glycemic control and duration of diabetes. Regarding the chronological evolution, retinopathy precedes nephropathy. Diabetic nephropathy (DN) was present in 10.6% of cases especially in patients with PDR. In summary, the frequency of PDR was higher than that of NPDR. DR appears before DN with a high frequency of DN in patients with PDR. Good glycemic control and blood pressure control, as well as early diagnosis are the major preventive measures against DR. (C) 2020 The Authors. Published by Elsevier B.V.
引用
收藏
页码:775 / 784
页数:10
相关论文
共 103 条
[1]   Screening for diabetic retinopathy by non-mydriatic retinal camera in the region of Fez [J].
Abdellaoui, M. ;
Marrakchi, M. ;
Benatiya, I. A. ;
Tahri, H. .
JOURNAL FRANCAIS D OPHTALMOLOGIE, 2016, 39 (01) :48-54
[2]   Risk factors associated with diabetic retinopathy among type 2 diabetes patients at teaching hospital in Malaysia [J].
Abougalambou, Salwa Selim Ibrahim ;
Abougalambou, Ayman S. .
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2015, 9 (02) :98-103
[3]  
Adham M., 2010, Eastern Mediterranean Health Journal, V16, P732
[4]   Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64) [J].
Adler, AI ;
Stevens, RJ ;
Manley, SE ;
Bilous, RW ;
Cull, CA ;
Holman, RR .
KIDNEY INTERNATIONAL, 2003, 63 (01) :225-232
[5]   Risk factors of diabetic retinopathy in Bangladeshi type 2 diabetic patients [J].
Ahmed, Kazi R. ;
Karim, Md N. ;
Bukht, Mohammad S. ;
Bhowmik, Bishwajit ;
Acharyya, Amitava ;
Ali, Liaquat ;
Hussain, Akhtar .
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2011, 5 (04) :196-200
[6]   Diabetic retinopathy and its risk factors in a society with a type 2 diabetes epidemic: a Saudi National Diabetes Registry-based study [J].
Al-Rubeaan, Khalid ;
Abu El-Asrar, Ahmed M. ;
Youssef, Amira M. ;
Subhani, Shazia N. ;
Ahmad, Najlaa A. ;
Al-Sharqawi, Ahmad H. ;
Alguwaihes, Abdullah ;
Alotaibi, Metib S. ;
Al-Ghamdi, Ali ;
Ibrahim, Heba M. .
ACTA OPHTHALMOLOGICA, 2015, 93 (02) :E140-E147
[7]  
ANDERSEN AR, 1983, DIABETOLOGIA, V25, P496
[8]   Glycemic Targets [J].
不详 .
DIABETES CARE, 2015, 38 :S33-S40
[9]  
[Anonymous], 1995, Diabetes, V44, P1249
[10]  
[Anonymous], 2017, Prof. Med. J.